Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis

Free Radical Biology and Medicine

Volumn 49, Issue 10, 2010, Pages 1480-1486

  Duryee, Michael J ^a,b   Klassen, Lynell W ^a,b   Schaffert, Courtney S ^a,b   Tuma, Dean J ^a,b   Hunter, Carlos D ^a,b   Garvin, Robert P ^a   Anderson, Daniel R ^a   Thiele, Geoffrey M ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Acetaldehyde; Atherosclerosis; Autoantibodies; JCR rats; Lipid peroxidation; Malondialdehyde; Modified proteins

Indexed keywords

ACETALDEHYDE; ADJUVANT; ANTIBODY; CARRIER PROTEIN; DIHYDROPYRIDINE; EPITOPE; MALONALDEHYDE; MALONALDEHYDE ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; AORTA; ARTICLE; ATHEROSCLEROSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; IMMUNE RESPONSE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION;

ACETALDEHYDE; ANIMALS; AORTA; ATHEROSCLEROSIS; DIHYDROPYRIDINES; EPITOPES; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED BALB C; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

MUS; RATTUS;

EID: 77957755375     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.08.001     Document Type: Article

References (46)

1. Uchida K. Lipofuscin-like fluorophores originated from malondialdehyde. Free Radic. Res. 2006, 40:1335-1338.
2. Steinbrecher U.P., Fisher M., Witztum J.L., Curtiss L.K. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J. Lipid Res. 1984, 25:1109-1116.
3. Yamada S., Kumazawa S., Ishii T., Nakayama T., Itakura K., Shibata N., Kobayashi M., Sakai K., Osawa T., Uchida K. Immunochemical detection of a lipofuscin-like fluorophore derived from malondialdehyde and lysine. J. Lipid Res. 2001, 42:1187-1196.
4. Fu S., Davies M.J., Stocker R., Dean R.T. Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochem. J. 1998, 333(Pt 3):519-525.
5. Heinecke J.W. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998, 141:1-15.
6. Holvoet P., Perez G., Zhao Z., Brouwers E., Bernar H., Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 1995, 95:2611-2619.
7. Palinski W., Horkko S., Miller E., Steinbrecher U.P., Powell H.C., Curtiss L.K., Witztum J.L. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 1996, 98:800-814.
8. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA 1989, 86:1372-1376.
9. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 1989, 84:1086-1095.
10. Herrmann J., Soares S.M., Lerman L.O., Lerman A. Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. J. Am. Coll. Cardiol. 2008, 51:2003-2010.
11. Horkko S., Binder C.J., Shaw P.X., Chang M.K., Silverman G., Palinski W., Witztum J.L. Immunological responses to oxidized LDL. Free Radic. Biol. Med. 2000, 28:1771-1779.
12. Matsuura E., Lopez L.R. Autoimmune-mediated atherothrombosis. Lupus 2008, 17:878-887.
13. Chou M.Y., Fogelstrand L., Hartvigsen K., Hansen L.F., Woelkers D., Shaw P.X., Choi J., Perkmann T., Backhed F., Miller Y.I., Horkko S., Corr M., Witztum J.L., Binder C.J. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J. Clin. Invest. 2009, 119:1335-1349.
14. Fredrikson G.N., Hedblad B., Berglund G., Alm R., Ares M., Cercek B., Chyu K.Y., Shah P.K., Nilsson J. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:872-878.
15. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84:1381-1478.
16. Tuma D.J., Thiele G.M., Xu D., Klassen L.W., Sorrell M.F. Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration. Hepatology 1996, 23:872-880.
17. Kikugawa K., Kato T., Iwata A. Determination of malonaldehyde in oxidized lipids by the Hantzsch fluorometric method. Anal. Biochem. 1988, 174:512-521.
18. Thiele G.M., Tuma D.J., Willis M.S., Miller J.A., McDonald T.L., Sorrell M.F., Klassen L.W. Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant. Alcohol. Clin. Exp. Res. 1998, 22:1731-1739.
19. Duryee M.J., Klassen L.W., Freeman T.L., Willis M.S., Tuma D.J., Thiele G.M. Lipopolysaccharide is a cofactor for malondialdehyde-acetaldehyde adduct-mediated cytokine/chemokine release by rat sinusoidal liver endothelial and Kupffer cells. Alcohol. Clin. Exp. Res. 2004, 28:1931-1938.
20. Willis M.S., Thiele G.M., Tuma D.J., Klassen L.W. T cell proliferative responses to malondialdehyde-acetaldehyde haptenated protein are scavenger receptor mediated. Int. Immunopharmacol. 2003, 3:1381-1399.
21. Duryee M.J., Willis M.S., Freeman T.L., Kuszynski C.A., Tuma D.J., Klassen L.W., Thiele G.M. Mechanisms of alcohol liver damage: aldehydes, scavenger receptors, and autoimmunity. Front. Biosci. 2004, 9:3145-3155.
22. ε-(2-propenol)lysine in proteins. Arch. Biochem. Biophys. 1997, 346:45-52.
23. Iwata A., Kikugawa K. Fluorometric determination of malonaldehyde in oxidized lipids. Chem. Pharm. Bull. (Tokyo) 1987, 35:5020-5023.
24. Thiele G.M., Tuma D.J., Miller J.A., Wegter K.M., McDonald T.L., Klassen L.W. Monoclonal and polyclonal antibodies recognizing acetaldehyde-protein adducts. Biochem. Pharmacol. 1998, 56:1515-1523.
25. Vine D.F., Takechi R., Russell J.C., Proctor S.D. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007, 190:282-290.
26. Schaffert C.S., Sorrell M.F., Tuma D.J. Expression and cytoskeletal association of integrin subunits is selectively increased in rat perivenous hepatocytes after chronic ethanol administration. Alcohol. Clin. Exp. Res. 2001, 25:1749-1757.
27. Thiele G.M., Klassen L.W., Tuma D.J. Formation and immunological properties of aldehyde-derived protein adducts following alcohol consumption. Meth. Mol. Biol. 2008, 447:235-257.
28. Xu D., Thiele G.M., Kearley M.L., Haugen M.D., Klassen L.W., Sorrell M.F., Tuma D.J. Epitope characterization of malondialdehyde-acetaldehyde adducts using an enzyme-linked immunosorbent assay. Chem. Res. Toxicol. 1997, 10:978-986.
29. Hill G.E., Miller J.A., Baxter B.T., Klassen L.W., Duryee M.J., Tuma D.J., Thiele G.M. Association of malondialdehyde-acetaldehyde (MAA) adducted proteins with atherosclerotic-induced vascular inflammatory injury. Atherosclerosis 1998, 141:107-116.
30. Mooradian A.D., Reinacher D., Li J.P., Pinnas J.L. Malondialdehyde modification of proteins in vitro is enhanced in the presence of acetaldehyde. Nutrition 2001, 17:619-622.
31. Tsai L., Szweda P.A., Vinogradova O., Szweda L.I. Structural characterization and immunochemical detection of a fluorophore derived from 4-hydroxy-2-nonenal and lysine. Proc. Natl. Acad. Sci. USA 1998, 95:7975-7980.
32. Duryee M.J., Freeman T.L., Willis M.S., Hunter C.D., Hamilton B.C., Suzuki H., Tuma D.J., Klassen L.W., Thiele G.M. Scavenger receptors on sinusoidal liver endothelial cells are involved in the uptake of aldehyde-modified proteins. Mol. Pharmacol. 2005, 68:1423-1430.
33. Thiele G.M., Duryee M.J., Freeman T.L., Sorrell M.F., Willis M.S., Tuma D.J., Klassen L.W. Rat sinusoidal liver endothelial cells (SECs) produce pro-fibrotic factors in response to adducts formed from the metabolites of ethanol. Biochem. Pharmacol. 2005, 70:1593-1600.
34. Bourdel-Marchasson I., Delmas-Beauvieux M.C., Peuchant E., Richard-Harston S., Decamps A., Reignier B., Emeriau J.P., Rainfray M. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001, 30:235-241.
35. Ishii T., Kumazawa S., Sakurai T., Nakayama T., Uchida K. Mass spectroscopic characterization of protein modification by malondialdehyde. Chem. Res. Toxicol. 2006, 19:122-129.
36. Kinalski M., Sledziewski A., Telejko B., Zarzycki W., Kinalska I. Lipid peroxidation and scavenging enzyme activity in streptozotocin-induced diabetes. Acta Diabetol. 2000, 37:179-183.
37. Klassen L.W., Thiele G.M. Immune reactivity to proteins biotransformed by alcohol metabolites. Alcohol. Clin. Exp. Res. 1998, 22:204S-207S.
38. Hawkins R.D., Kalant H. The metabolism of ethanol and its metabolic effects. Pharmacol. Rev. 1972, 24:67-157.
39. Visapaa J.P., Jokelainen K., Nosova T., Salaspuro M. Inhibition of intracolonic acetaldehyde production and alcoholic fermentation in rats by ciprofloxacin. Alcohol. Clin. Exp. Res. 1998, 22:1161-1164.
40. Edgar A.J. Mice have a transcribed l-threonine aldolase/GLY1 gene, but the human GLY1 gene is a non-processed pseudogene. BMC Genomics 2005, 6:32.
41. Ma X.L., Baraona E., Hernandez-Munoz R., Lieber C.S. High levels of acetaldehyde in nonalcoholic liver injury after threonine or ethanol administration. Hepatology 1989, 10:933-940.
42. Seeman J.I., Dixon M., Haussmann H.J. Acetaldehyde in mainstream tobacco smoke: formation and occurrence in smoke and bioavailability in the smoker. Chem. Res. Toxicol. 2002, 15:1331-1350.
43. Freeman T.L., Haver A., Duryee M.J., Tuma D.J., Klassen L.W., Hamel F.G., White R.L., Rennard S.I., Thiele G.M. Aldehydes in cigarette smoke react with the lipid peroxidation product malonaldehyde to form fluorescent protein adducts on lysines. Chem. Res. Toxicol. 2005, 18:817-824.
44. Harats D., Ben-Naim M., Dabach Y., Hollander G., Stein O., Stein Y. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis 1989, 79:245-252.
45. Nielsen F., Mikkelsen B.B., Nielsen J.B., Andersen H.R., Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin. Chem. 1997, 43:1209-1214.
46. Sandhir R., Subramanian S., Koul A. Long-term smoking and ethanol exposure accentuates oxidative stress in hearts of mice. Cardiovasc. Toxicol. 2003, 3:135-140.